Showing results (341-350 of 523) with videos related to
Sort By:
Pageof 53
Cancers|December 17, 2024
Association of Lung Immune Prognostic Index (LIPI) with Disease Control Rate and Progression-Free Survival in Patients with Soft-Tissue Sarcoma Treated with Immunotherapy in Early-Phase TrialsMarianne Zoghbi, Brina A Patel, Matthieu Roulleaux Dugage, et al.The Lancet. Oncology|October 28, 2017
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialAlice T Shaw, Enriqueta Felip, Todd M Bauer, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2022
Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001Caroline E McCoach, Christian Rolfo, Alexander Drilon, et al.European Journal of Cancer (Oxford, England : 1990)|January 18, 2019
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancerBenjamin P Levy, Giuseppe Giaccone, Benjamin Besse, et al.Annales De Pathologie|December 14, 2020
[Thymoma and squamous thymic carcinoma diagnosis; experience from the RYTHMIC network]Lara Chalabreysse, Romain Dubois, Véronique Hofman, et al.Journal for Immunotherapy of Cancer|November 29, 2024
Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancerFilippo G Dall'Olio, Wael Salem Zrafi, Quentin Blampey, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2020
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and RecommendationsJordi Remon, Francesco Passiglia, Myung-Ju Ahn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2017
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET RegistryOliver Gautschi, Julie Milia, Thomas Filleron, et al.European Journal of Cancer (Oxford, England : 1990)|November 1, 2019
EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic diseaseAntonin Levy, Lizza E L Hendriks, Thierry Berghmans, et al.Med (New York, N.Y.)|May 19, 2022
Liquid biopsies for residual disease and recurrenceJonathan Chee Ming Wan, Tariq Imdadali Mughal, Pedram Razavi, et al.Pageof 53